Current Status of HER2 Testing

Publisher： Karger

E-ISSN： 1423-0232|63|1|25-32

ISSN： 0030-2414

Source： Oncology, Vol.63, Iss.1, 2002-11, pp. : 25-32

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Testing for HER2 Status

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 22-30

Karger

Access to resources Recommend Favorite

Emerging Technologies for HER2 Testing

By  

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 33-38

Karger

Access to resources Recommend Favorite

HER2 status is an important biomarker in guiding personalized HER2 therapy

By Carney Walter P  

Personalized Medicine, Vol. 2, Iss. 4, 2005-11 ,pp. : 317-324

Future Medicine

Access to resources Recommend Favorite

The FlexISH assay brings flexibility to cytogenetic HER2 testing

By  

HISTOPATHOLOGY, Vol. 69, Iss. 4, 2016-10 ,pp. : 635-646

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer

By  

CANCER, Vol. 120, Iss. 17, 2014-09 ,pp. : 2657-2664

John Wiley & Sons Inc

Access to resources Recommend Favorite